Purpose of Preoperative MRSA Swab
The primary purpose of preoperative MRSA swab screening is to identify colonized patients who can then undergo targeted decolonization (with mupirocin ± chlorhexidine) and receive modified perioperative antibiotic prophylaxis to reduce surgical site infections, particularly in high-risk surgeries like cardiac and orthopedic procedures. 1
The Screen-and-Treat Strategy
MRSA screening alone does not reduce infections—it must be coupled with intervention. The 2024 European guidelines emphasize that screening is only valuable when part of a "screen-and-decolonize" protocol 1. One study showed that rapid MRSA screening without subsequent decolonization failed to reduce nosocomial MRSA infections 1. The screening identifies which patients need:
- Decolonization therapy: Mupirocin 2% nasal ointment twice daily for 5 days ± chlorhexidine gluconate soap
- Modified antibiotic prophylaxis: Addition of vancomycin to standard prophylaxis for MRSA carriers in cardiac, orthopedic, and neurosurgery 1
Which Patients Should Be Screened
Screen patients undergoing high-risk elective surgeries where S. aureus infections carry severe consequences 1:
- Cardiac/cardiothoracic surgery (strong recommendation)
- Orthopedic surgery, especially joint arthroplasty (strong recommendation)
- Neurosurgery involving prosthetic material
- Consider for other surgeries based on local epidemiology
The decision between universal screening (all patients) versus targeted screening (based on risk factors like prior MRSA infection, recent hospitalization, healthcare exposure) should depend on local MRSA prevalence, laboratory capacity, and available resources 1.
Clinical Impact of Screening
The evidence demonstrates tangible benefits when screening is linked to action:
- Decolonization reduces SA-SSIs: Meta-analyses show mupirocin-based decolonization reduces MRSA-SSIs (RR 0.30) and MSSA-SSIs (RR 0.50) 1
- Colonization predicts infection risk: MRSA-positive patients have higher readmission rates, longer hospital stays, and increased septic and aseptic revision rates even with decolonization 2
- Prevalence varies: Studies report 1-5% MRSA colonization rates in surgical populations 3, 4, 5
Important Caveats
Screening methodology matters. While nasal swabs are standard, 5-10% of MRSA carriers may be nasal-negative but positive at other sites (groin, perianal) 5. However, multi-site screening increases cost and complexity.
Timing is critical: Complete decolonization 1-2 weeks before surgery, as close to the operative date as possible 1. Approximately 3-4% of patients may fail initial decolonization and require repeat treatment 4.
Resistance concerns: Universal decolonization without screening risks mupirocin resistance development 1. This is why targeted screening-based approaches are preferred over blanket decolonization.
Cost-Effectiveness
Targeted screening using risk-based questionnaires (identifying patients with recent hospitalization, prior MRSA history, healthcare work, or farming exposure) achieves approximately 79% cost reduction compared to universal screening while maintaining detection efficacy 3. The cost of screening (typically $20-50 per test) is offset by preventing even a single prosthetic joint infection, which costs $50,000-100,000 to treat.
Implementation Framework
The guidelines recommend screening only in centers where it is feasible and where results can be acted upon 1. Implementation requires:
- Laboratory capacity for timely results (ideally rapid molecular testing)
- Established decolonization protocols
- Coordination between surgical, infection control, and antimicrobial stewardship teams
- Local epidemiologic data to justify the intervention
Bottom line: MRSA screening is not a standalone infection prevention measure but rather the first step in a targeted intervention pathway that reduces surgical site infections in high-risk procedures through decolonization and tailored antibiotic prophylaxis.